Genenta Science SPA (Genenta Science SPA) EBIT : $-12.75 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA EBIT?

Genenta Science SPA's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-5.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genenta Science SPA's annualized ROC % for the quarter that ended in Dec. 2023 was -392.56%. Genenta Science SPA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10,599.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genenta Science SPA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -32.00%.

Genenta Science SPA EBIT Historical Data

The historical data trend for Genenta Science SPA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA EBIT Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-5.10

-6.80

-6.26

-11.70

-12.80

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial				-1.69	-4.39	-7.30	-7.37	-5.38

Competitive Comparison of Genenta Science SPA's EBIT

For the Biotechnology subindustry, Genenta Science SPA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's EV-to-EBIT falls into.

Genenta Science SPA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12.75 Mil.

Genenta Science SPA (NAS:GNTA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genenta Science SPA's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-10.758 * ( 1 - 0% )	/	( (3.201	+	2.28)	/ 2 )
=	-10.758	/	2.7405
=	-392.56 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.956	-	1.69	-	( 24.065	-	max(0, 1.92	-	26.561	+	24.065	))
=	3.201

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.37	-	1.615	-	( 20.475	-	max(0, 1.893	-	23.18	+	20.475	))
=	2.28

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Genenta Science SPA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-10.758	/	( ( (0.112 + max(-1.52, 0))	+	(0.091 + max(-1.373, 0)) )	/	2 )
=	-10.758	/	( ( 0.112	+	0.091 )	/	2 )
=	-10.758	/	0.1015
=	-10,599.01 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.4)	-	(1.69	+	0	+	0.23)
=	-1.52

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.52)	-	(1.615	+	0	+	0.278)
=	-1.373

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genenta Science SPA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-12.746	/	39.836
	=	-32.00 %

Genenta Science SPA EBIT Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.